Advances in Gene Therapy for the Management of Neurodegenerative Diseases

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This Genetic Technology TOE depicts recent advances in gene therapy for the management of neurodegenerative diseases. Genetic technology advances are likely to open novel avenues across gene therapy for management of neurodegenerative diseases. This study focusses on some important innovations in the field. The corresponding clinical trial scenario is depicted along with the industry interactions.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is co

Table of Contents

Advances in Gene Therapy for the Management of Neurodegenerative DiseasesAdvances in Gene Therapy for the Management of Neurodegenerative DiseasesTargeting Cholesterol Metabolism in Huntington’s and Alzheimer’s DiseasesReprogramming Retromers for Neurodegenerative DiseasesTargeting Aromatic L-amino Acid Decarboxylase in Parkinson’s DiseaseTelomerase Gene Therapy For Alzheimer’s DiseaseClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.